The researchers from the Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of Sciences, N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry of the Siberian Branch of the Russian Academy of Sciences, and E.N. Meshalkin Siberian Federal Biomedical Research Center created a drug to stop the bleeding in open surgery, including open-heart procedures.
The new drug includes vancomycin, an antibiotic used as the first-line medicine in the treatment of infectious complications of cardiovascular surgery, and oxidized cellulose, a well-known hemostatic agent.
“This newly developed medication quickly and effectively stops bleeding, has antibacterial activity, and is biocompatible and biodegradable. It is available in two forms, including fine powder and paste. The drug can be used in a fairly extensive range of surgery areas, including operations on the heart,” said Alexandra R. Tarkova, a researcher at the Center for Aorta, Coronary and Peripheral Arteries Surgery of E.N. Meshalkin Siberian Federal Biomedical Research Center and Candidate of Medical Sciences. “As of today, we completed the pilot preclinical studies, both in vitro and in vivo, created a product prototype, obtained a patent, and are currently negotiating with an official industrial partner.”